Connealy Pamela Ann

SEC source: 0001104659-26-077775 · tm2618965-3_4seq1.xml · derivative · entry 2

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,277

Underlying: Common Stock · 21,277 shares

Expires 2036-06-23

F2 · derivative.exercise_date: The stock options will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

SEC source: 0001104659-26-077775 · tm2618965-3_4seq1.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,038

F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 23, 2026 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

SEC source: 0001104659-25-075786 · tm2523004-7_4seq1.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,711

F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on August 7, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.

SEC source: 0001104659-25-063095 · tm2519252-3_4seq1.xml · derivative · entry 2

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,797

Underlying: Common Stock · 36,797 shares

Expires 2035-06-24

F2 · derivative.exercise_date: The stock options will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.

SEC source: 0001104659-25-063095 · tm2519252-3_4seq1.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,711

F1 · shares: Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 24, 2025 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest in one installment on the earlier of (x) the one year anniversary of the Grant Date or (y) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such dates.

SEC source: 0000950170-25-048893 · ownership.xml · derivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 414,163

Underlying: Common Stock · 414,163 shares

Expires 2035-03-31

F1 · derivative.exercise_date: The shares subject to this option will vest over four years, with 25% vesting on the first anniversary of March 31, 2025 and the remainder vesting in 36 equal monthly installments thereafter subject to the reporting person's continued emmployment through the applicable vesting date.

SEC source: 0000950170-24-139608 · ownership.xml · derivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 310,000

Underlying: Common Stock · 310,000 shares

Expires 2034-12-23

F1 · derivative.exercise_date: The shares subject to this option vest in full on December 23, 2025, subject to the Reporting Person's continued employment through the vesting date.

SEC source: 0000950170-24-131606 · ownership.xml · nonDerivative · entry 2

Connealy Pamela Ann · CIK 0001796310 · CFO & COO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 1,199,143

F2 · price: The price reported in column 4 is a weighted-average price.These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

SEC source: 0000950170-24-131606 · ownership.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO & COO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 1,115,743

F1 · ownership.nature: These shares are held directly by the Personal Def Ben Pln Trust, a revocable trust for which the Reporting Person and their spouse are the trustees.

SEC source: 0001104659-24-074013 · tm2417742-5_4seq1.xml · derivative · entry 2

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,068

Underlying: Common Stock · 17,068 shares

Expires 2034-06-20

SEC source: 0001104659-24-074013 · tm2417742-5_4seq1.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,289

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on June 20, 2025.

SEC source: 0000950170-24-038108 · ownership.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,110,293

F1 · shares: Represents restricted stock units that vest 25% on the first anniversary of March 26, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001209191-23-056969 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 781,583

F1 · shares: Represents shares withheld to cover taxes due upon the vesting of certain restricted stock units.

SEC source: 0001209191-23-050734 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 818,532

F1 · price: The Reporting Person purchased all 8,000 shares of common stock in the open market at a price of $1.87 per share.

SEC source: 0001209191-23-050685 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 810,532

F1 · price: Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.78 to $1.87 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price.

SEC source: 0001209191-23-050492 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 804,106

F1 · price: Represents the weighted average purchase price of common stock purchased by the Reporting Person in open market transactions. The range of purchase prices on the transaction date was $1.615 to $1.70 per share. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each price.

SEC source: 0001209191-23-050432 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 792,106

F1 · price: The Reporting Person purchased all 5,000 shares of common stock in the open market at a price of $1.739 per share.

SEC source: 0001209191-23-048819 · doc4.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 782,106

F1 · shares: Represents restricted stock units that are fully vested.

SEC source: 0001104659-23-083499 · tm2321855-6_4seq1.xml · derivative · entry 2

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2033-07-20

SEC source: 0001104659-23-083499 · tm2321855-6_4seq1.xml · nonDerivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,913

F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest on the first anniversary of the grant date.

SEC source: 0001213900-23-037027 · ownership.xml · derivative · entry 2

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 758

Underlying: Common Stock · 758 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · derivative.exercise_price: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · derivative.exercise_date: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

F1 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · derivative.expiration_date: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

SEC source: 0001213900-23-037027 · ownership.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,246

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · kind: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the "Initial Milestone Event") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · price: The Initial Milestone Event occurred on April 12, 2023 and 758 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement.

SEC source: 0001209191-23-021413 · doc4.xml · derivative · entry 5

Yanchik Connealy Pamela · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,304

Underlying: Common Stock · 10,304 shares

Expires 2031-09-14

F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F4 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001209191-23-021413 · doc4.xml · derivative · entry 4

Yanchik Connealy Pamela · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,265

Underlying: Common Stock · 322,265 shares

Expires 2031-07-30

F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F3 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the July 31, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001209191-23-021413 · doc4.xml · derivative · entry 3

Yanchik Connealy Pamela · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,304 shares

Expires 2031-09-14

F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F4 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the closing of the Issuer's initial public offering, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001209191-23-021413 · doc4.xml · derivative · entry 2

Yanchik Connealy Pamela · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 322,265 shares

Expires 2031-07-30

F2 · derivative.exercise_price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F2 · price: In accordance with the terms of the Pyxis Oncology, Inc. 2019 Equity and Incentive Plan (the "Plan"), the Board of Directors of Pyxis Oncology, Inc. approved a stock option repricing pursuant to which option awards granted under the Plan were amended to reduce the exercise price to $2.21 per share, the closing stock price on the date of Board approval. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.

F3 · derivative.exercise_date: These stock options vested 25% on the first anniversary of the July 31, 2021 grant date, and then vests in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001209191-23-021413 · doc4.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 594,313

F1 · shares: Represents restricted stock units that vest 25% on March 24, 2024, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001213900-23-006193 · ownership.xml · derivative · entry 3

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,250

Underlying: Common Stock · 23,250 shares

Expires 2032-08-25

F6 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share.

F5 · derivative.exercise_date: The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such date. The grant date is August 18, 2022.

SEC source: 0001213900-23-006193 · ownership.xml · derivative · entry 2

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,600

Underlying: Common Stock · 18,600 shares

Expires 2030-06-29

F4 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 40,000 shares of Legacy Orchestra Common Stock for $3.56 per share.

F3 · derivative.exercise_date: The nonstatutory stock options ("NSOs") have vested and will vest in equal installments over a three-year period on a quarterly basis, starting with the last day of the last month of the first quarter after the grant date, subject to the Reporting Person's continuous service through such date. The grant date is June 30, 2020.

SEC source: 0001213900-23-006193 · ownership.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,488

F1 · shares: These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities.

F2 · price: Received in the Business Combination in exchange for 7,500 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock").

SEC source: 0001213900-23-037017 · ownership.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,516

Underlying: Common Stock · 1,516 shares

Expires not disclosed

F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently omitted the right to receive Earnout Shares (defined below). In accordance with Instruction 9(a) to Form 4, this amendment is filed solely to add the lines of information to Table II included here; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing.

F2 · derivative.exercise_price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the "Merger Agreement"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the "Earnout Shares") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period.

SEC source: 0001213900-23-041623 · ownership.xml · derivative · entry 1

Connealy Pamela Ann · CIK 0001796310 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,250

Underlying: Common Stock · 23,250 shares

Expires 2032-08-17

F1 · security: On January 30, 2023, the Reporting Person filed a Form 4 which inadvertently misstated the expiration date of one class of nonstatutory stock options ("NSOs"). In accordance with Instruction 9(b) to Form 4, this amendment is filed solely to correct the incorrect expiration date in Table II, Column 6 to August 17, 2032; as provided in that instruction, the remainder of the information in the original filing is not restated in this amendment, and no other amendment is made to the original filing.

F3 · price: Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share.

F2 · derivative.exercise_date: The NSOs vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such date. The grant date is August 18, 2022.

SEC source: 0001567619-23-000066 · doc1.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 384,510

F1 · shares: Represents restricted stock units that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

SEC source: 0001567619-22-008615 · doc1.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,017

F1 · shares: Represents restricted stock units ("RSUs") that vest on April 13, 2023, subject to the Reporting Person's continued employment through the vesting date.

F2 · shares: The Compensation Committee also approved a grant to the Reporting Person, effective January 3, 2023, of an additional 43,493 RSUs that vest on April 13, 2023, subject to the Reporting Person's continued employment through the grant and vesting dates.

SEC source: 0001140361-22-012916 · form4.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,524

F1 · shares: Represents restricted stock units that vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting in 12 substantially-equal quarterly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0000899243-21-047102 · doc4.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,944

Underlying: Common Stock · 52,944 shares

Expires 2031-12-06

F1 · derivative.exercise_date: These stock options vest 25% on July 19, 2022, and then in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.

SEC source: 0001764013-21-000039 · wf-form4_161650350410303.xml · derivative · entry 2

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 162,000

Underlying: Common Stock · 162,000 shares

Expires 2031-03-19

F3 · derivative.exercise_date: Shares underlying the options vest over four years, with 25% of the shares underlying the options vesting on March 19, 2022 and the remainder of the shares underlying the options vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001764013-21-000039 · wf-form4_161650350410303.xml · nonDerivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,200

F1 · security: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2 · shares: The RSUs vest over four years, with 25% of the RSUs vesting on March 19, 2022 and the remainder of the RSUs vesting in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-20-029930 · doc4.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,500

Underlying: Common Stock · 180,500 shares

Expires 2030-05-14

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

SEC source: 0001209191-19-061603 · doc4.xml · derivative · entry 1

Yanchik Connealy Pamela · CIK 0001796310 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 433,588

Underlying: Common Stock · 433,588 shares

Expires 2029-11-19

F2 · price: In connection with the share exchange transaction pursuant to which Health Sciences Acquisitions Corporation ("HSAC") acquired 100% of the issued and outstanding shares of Immunovant Sciences Ltd., the option to purchase 886,563 shares of Immunovant Sciences Ltd. at exercise price of $4.12 per share, was assumed by HSAC and converted into an option to purchase shares of the Issuer (formerly known as HSAC).

F1 · derivative.exercise_date: 25% of the shares underlying the option vests on the first anniversary of the grant date, and the remainder vests in 12 equal quarterly installments thereafter.